POLA+BR for Relapsed or Refractory DLBCL

Summary

This is a phase II multicenter, open-label study of polatuzumab vedotin administered by IV infusion in combination with standard doses of bendamustine (B) and rituximab (R) in transplant-eligible patients with relapsed or refractory DLBCL. A total of 22 patients will be enrolled over a period of 2 years through the University of Colorado and additional study sites if applicable. Study treatment will be given in 21-day cycles for patients with DLBCL.

Timeline

Start

2021-01-29

Primary completion

2022-03-17

Completion

2022-03-17

Drugs

Indications